Seres Therapeutics, Inc.
HealthcareNASDAQ:MCRB · NASDAQ Global Select
-$0.62 today
Vol 0.11M · Avg 0.05M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
12.9%
avg -282.7%
ROIC
-72.7%
avg -64.4%
ROA
4.1%
avg -44.5%
Analysis
ROE is currently the strongest return metric at 12.9% versus its period average of -282.7%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Thomas J. DesRosier | Executive VP, Chief Legal Officer & Secretary | $689,733.00 | — | 71 | $7,954.00 | 0.08% |
Marella Thorell | Executive VP, CFO & Treasurer | $667,106.00 | — | 59 | $22,500.00 | 0.23% |
Matthew R. Henn | President & Chief Scientific Officer | $492,375.00 | — | 51 | $7,838.00 | 0.08% |
Chris McChalicher | Executive Vice President & Chief Technology Officer | $142,708.00 | — | — | — | — |
Richard N. Kender | Interim CEO & Executive Chair | $72,500.00 | — | 70 | $150,000.00 | 1.55% |
Dennis Walling | Senior Vice President of Clinical Development & Head of Clinical Research | — | — | — | $6,452.00 | 0.07% |
Ann Kurowski | Senior Vice President of Regulatory Affairs | — | — | — | — | — |
Kelly Brady | Executive VP & COO | — | — | 42 | $8,562.00 | 0.09% |
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
0
$0.00
Sells
16
$59,730.54
Net Sentiment
$59,730.54
Net selling
Most Active
Shaff Eric D.
4 transactions
1–10 of 16
Analysis
Insiders reported 0 buys worth $0.00 and 16 sells worth $59,730.54 over the last 12 months. That adds up to net selling of $59,730.54. Shaff Eric D. was the most active insider with 4 transactions.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A1 analysts |
| Revenue | N/A | N/A | N/A | -29.1% (13yr)1 analysts |
| Net Income | N/A | N/A | N/A | N/A1 analysts |
| EBIT | N/A | N/A | N/A | N/A1 analysts |
Analysis
Forward estimates point to Revenue at -29.1% (13yr), giving you a quick read on expected growth from here.
Competitors
Peer companies in the same sector
Opus Genetics, Inc.
NASDAQ:IRD
$328.84M
Spero Therapeutics, Inc.
NASDAQ:SPRO
$165.02M
TuHURA Biosciences, Inc.
NASDAQ:HURA
$147.74M
Acumen Pharmaceuticals, Inc.
NASDAQ:ABOS
$143.56M
Seer, Inc.
NASDAQ:SEER
$94.57M
Cognition Therapeutics, Inc.
NASDAQ:CGTX
$89.03M
Inovio Pharmaceuticals, Inc.
NASDAQ:INO
$58.95M
Actuate Therapeutics Inc
ACTU
$48.33M
VistaGen Therapeutics, Inc.
VTGN
$18.88M
Applied Therapeutics, Inc.
APLT
$14.86M
Who manages MCRB?
Seres Therapeutics, Inc. (MCRB) lists 8 active executives. The top listed executive is Marella Thorell, Executive VP, CFO & Treasurer.
Are MCRB insiders buying or selling?
Recent insider activity shows net buying of $7.78M.
Explore More
Continue the stock analysis
Jump to another research area for this company.